Welcome to our dedicated page for Merit Med Sys news (Ticker: MMSI), a resource for investors and traders seeking the latest updates and insights on Merit Med Sys stock.
Merit Medical Systems Inc. develops, manufactures and distributes proprietary medical devices used in interventional, diagnostic and therapeutic procedures, with product activity concentrated in cardiology, radiology, oncology, critical care and endoscopy. Company news commonly covers operating results, annual guidance, revenue presentation by Foundational and Therapeutic product categories, and portfolio actions involving acquired or divested device lines.
Recurring updates also include commercial launches and distribution arrangements for products such as the Resilience Through-the-Scope Esophageal Stent, ViaVerte basivertebral nerve ablation system, OneMark Detection Imaging System and OneMark Tissue Markers. Governance announcements and healthcare conference participation appear alongside financial and product disclosures.
Merit Medical Systems (NASDAQ: MMSI) appointed Sheri Lewis as Executive Vice President of Global Operations, effective August 31, 2026. She brings about 30 years of experience in global operations, manufacturing, and supply chain leadership at several major healthcare and industrial companies.
Current Chief Operating Officer Neil Peterson will transition to Senior Advisor through March 5, 2027, then conclude more than 32 years of service after holding multiple operations and engineering leadership roles.
Merit Medical (NASDAQ: MMSI) will participate in two August 2026 investor conferences. Management will join a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11 at 11:00 a.m. ET and at the Bank of America SMID Cap Conference, held virtually, on August 12 at 9:00 a.m. ET. Live audio webcasts and 90-day replays will be available in the Events section of Merit Medical’s investor relations website.
Merit Medical (NASDAQ:MMSI) reported second quarter 2026 revenue of $418.8 million, up 10% year-over-year, with constant currency and organic revenue each up 9%. U.S. sales grew 10%. GAAP gross margin improved to 51.4% and GAAP operating margin to 14.4%, while non-GAAP gross and operating margins reached 55.8% and 22.6%, respectively.
GAAP net income was $38.8 million (EPS $0.65), up 20%, and non-GAAP net income was $71.3 million (EPS $1.19), up 18%. Year-to-date operating cash flow was $110.0 million and free cash flow $76.6 million, down 11% and 14%. The company ended June 30, 2026 with $448.7 million in cash, $747.5 million in total debt, and about $697 million of available borrowing capacity. Merit raised its 2026 revenue guidance to $1.631–$1.643 billion (8% growth) and non-GAAP EPS guidance to $4.25–$4.35 (11–14% growth).
Merit Medical Systems (NASDAQ:MMSI) will release its second quarter 2026 financial results for the period ended June 30, 2026, after market close on Thursday, July 30, 2026. An investor conference call will follow at 4:30 p.m. Eastern, with webcast and registration links available at www.merit.com.
Merit Medical (NASDAQ: MMSI) announced that shareholders elected Scott R. Ward to its Board of Directors at the May 19, 2026 annual meeting. Ward will serve a three-year term and join the Board’s Governance and Sustainability and Finance and Operating Committees.
Ward brings over 40 years of healthcare and medical device leadership, including senior roles at Medtronic, CEO and Chairman of Cardiovascular Systems during its sale to Abbott, and founder of Raymond Holdings.
Merit Medical (NASDAQ: MMSI) will participate in the Bank of America 2026 Health Care Conference in Las Vegas, May 12-14, 2026. Management will hold a fireside chat on Tuesday, May 12 at 3:00 PM PT / 6:00 PM ET.
A live audio webcast will be available under the company’s Events section and a replay will remain accessible for approximately 90 days.
Merit Medical Systems (NASDAQ: MMSI) reported Q1 2026 revenue of $381.9M (+7% reported; +5% constant currency; +3% organic) and GAAP EPS of $0.68 (up 39%). Non-GAAP EPS was $0.94 (up 9%), free cash flow was $24.7M (up 26%), and non-GAAP operating margin improved to 19.7%. Merit sold the DualCap product assets for $28M and acquired View Point Medical for $140M (paid $90M cash at closing). Full-year 2026 revenue guidance is $1.612–$1.634B; acquisition expected to add $2–$4M revenue and dilute non-GAAP EPS by ~$0.05.
Merit Medical (NASDAQ: MMSI) will release first quarter 2026 financial results after market close on Thursday, April 30, 2026. The company will hold an investor conference call the same day at 4:30 p.m. ET with a live webcast and slide deck available online.
Investors may pre-register for dial-in details; registration and webcast links will be posted at www.merit.com. Merit develops and distributes proprietary medical devices and employs about 7,600 people with over 800 sales and clinical support staff worldwide.
Merit Medical (NASDAQ: MMSI) acquired View Point Medical via merger, making View Point a Merit subsidiary effective April 1, 2026. The aggregate consideration is approximately $140 million including assumed liabilities, with $90 million paid at closing and two deferred $25 million payments.
Merit expects 2026 revenue contribution of $2M–$4M, 2027 contribution of $14M–$16M, near-term non‑GAAP EPS dilution of $0.05, and projects OneMark sales to grow ≥20% annually with ~70% non‑GAAP gross margins.
Medtronic entered a distribution agreement with Merit Medical Systems (NASDAQ: MMSI) to offer the FDA-cleared ViaVerte™ basivertebral nerve ablation (BVNA) system.
ViaVerte is a minimally invasive, implant-free, physician-steerable BVNA system for chronic vertebrogenic lower-back pain; it will be available later in 2026 and expands Medtronic's pain interventions portfolio.